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Ionizing radiation (IR) can induce DNA double-strand breaks (DSBs) in tumor cells during
radiotherapy (RT), but the efficiency of RT is limited because of the toxicity to normal cells.
Locating an adjuvant treatment to alleviate damage in normal cells while sensitizing tumor
cells to IR has attracted much attention. Here, using the 7,12-dimethylbenz[a]anthracene
(DMBA)-induced malignant transformed MCF10A cells, we found that valproate (VPA), a
histone deacetylase inhibitor (HDACi), radiosensitized transformed cells while alleviated
IR-induced damage in normal cells at a safe dose (0.5 mM). We further demonstrated the
decrease of homologous recombination (HR)-associated Rad51 in the transformed cells
was related to the increase of its ubiquitination regulated by E3 ligase RFWD3 for the
radiosensitization, which was opposite to normal cells, indicating that RFWD3-dependent
ubiquitination on Rad51 was involved in the VPA-mediated radio-bidirectional effect.
Through DMBA-transformed breast cancer rat model, VPA at 200 mg/kg radiosensitized
tumor tissue cells by increasing RFWD3 and inhibited Rad51, while radioprotected normal
tissue cells by decreasing RFWD3 and enhanced Rad51. In addition, we found high-level
Rad51 was associated with tumorigenesis and poor prognosis in breast cancer patients.
Our findings uncovered RFWD3-dependent Rad51 ubiquitination was the novel
mechanism of VPA-mediated radio-bidirectional effect, VPA is a potential adjuvant
treatment for tumor RT.
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INTRODUCTION
Radiotherapy (RT) has been proven effective in managing breast
cancer and other malignancies (1), but the toxicity and the
bystander adverse effect induced by ionizing radiation (IR)
have limited the popularity of this oncological treatment
modality (2–4). Furthermore, multiple tumor cells have shown
resistance to RT (5). Therefore, locating an efficacious and safe
oncological treatment modality is of clinical importance.
IR induces intracellular DNA damage, particularly the most
lethal DNA double-strand breaks (DSBs), and triggers
sophisticated DNA repair pathways, including error-free
homologous recombinat ion (HR) and error-prone
nonhomologous end-joining (NHEJ) (6). HR acts as an
effective DSBs repair pathway to keep genomic stability (5).
Rad51 has been identified as the central protein in HR, which
forms helical nucleoprotein filaments on tracts of single-strand
DNA (ssDNA) at DSBs sites (7). Rad51 also regulates stalled
replication forks by protecting newly synthesized DNA from
degradation (8, 9), promoting replication fork regression (9, 10),
and reinstates the collapsed replication forks (11).
As the DNA damage response (DDR) is initiated, DNA repair
proteins are recruited to damaged sites to repair DSBs. A cascade
of post-transcriptional modification (PTM) associated protein
interactions occur at the damaged sites, which serve as the codes
of DNA damage to recruiting specific proteins for repair (12).
DDR is exquisitely regulated by the modification of numerous
proteins, ubiquitination plays an important role (13), which has
been demonstrated to span a wide spectrum in many cellular
functions, including proteasomal degradation of proteins,
intracellular trafficking, inflammation signaling, and DNA
repair (14, 15). The deregulation of ubiquitination could also
result in oncogenesis and the dysfunction of the DNA repair
process (16, 17). Notably, the ubiquitination on Rad51 is
suggested as an important way to maintain HR function (18).
RFWD3, a novel E3 ligase, was found to be necessary for the
restart of the replication fork during the HR process (18, 19).
Current studies demonstrated that Rad51 can be ubiquitinated
by RFWD3, which is necessary for the restart of the replication
fork during the HR process (18). Rad51 directly interacts with
the N-terminal of RFWD3 and is ubiquitinated by RFWD3 (20,
21). Also, it is reported the loss of the ubiquitination of Rad51
leads to impaired HR (18). Since studies demonstrated that DDR
proteins may be potentially targeted for cancer therapy (22, 23),
thus, it would be important to locate a drug that can specially
target RFWD3-dependent Rad51 ubiquitination for
cancer therapy.
The anticonvulsant drug, valproate (VPA) is a class IIa
histone deacetylase inhibitor (HDACi) (24–27), it has been
demonstrated to sensitize multiple tumor cells to IR treatment,
increased intracellular toxicity, and a safe and effective
radiosensitizer following IR treatment. The radiosensitization
effect of HDACi was further found in glioma, lung cancer,
esophagus cancer, prostatic cancer, and colon cancer (24, 28–
32). Our previous studies showed that VPA, at a safe therapeutic
dose of 0.5 mM, sensitizes breast tumor MCF7 cells and the
primary cultured breast tumor cells to IR by impeding HR
function with Rad51 inhibition (33). Recent studies have
shown that VPA protects normal neuron cells under IR
treatment through regulating apoptosis, reactive oxygen species
(ROS) response, and Nrf2 translocation (31, 32, 34). The lethality
of mice after total-body irradiation was mitigated by
concomitant VPA treatment (35). Moreover, VPA reduced
hair loss and improved survival in high-grade glioma patients
during RT (36). Although the potential of VPA for being an
effective radioprotectant and radiosensitizer on normal neuron
and glioma cells has been demonstrated, the accurate mechanism
of this bidirectional effect of VPA upon IR-induced damage on
normal and malignant cells is still unclear.
In this study, we used the environmental carcinogen 7,12-
dimethylbenz[a]anthracene (DMBA) to establish a transformed
malignant cell from the human normal breast epithelial cell line
MCF10A. By this paired cell line, we found that VPA renders
radiosensitization effect on DMBA-transformed MCF10A cells
while the radioprotective effects on normal MCF10A.
Importantly, VPA-mediated radiosensitization effects on
transformed cells were associated with the up-regulation of
Rad51 ubiquitination mediated by RFWD3. In contrast, VPA-
mediated radioprotective effects on normal cells were due to
Rad51 ubiquitination down-regulated by RFWD3. Using a well-
established breast cancer rat model induced by DMBA, the
RFWD3-dependent Rad51 ubiquitination involved in the
VPA-mediated bidirectional effect under RT was also
confirmed. Our findings uncovered the molecular mechanism
of the bidirectional effect of VPA under IR treatment both in
vitro and in vivo, VPA would be able to target RFWD3 and
trigger Rad51 ubiquitination for cancer radiotherapy.
MATERIALS AND METHODS
Ionizing Radiation
IR was applied to rats and cells by using a Siemens Stabilipan 2X-
ray generator at 250 kVp 12 mA, at a dose rate of 2.08 Gy/min.
The schematic diagram of local irradiation on tumors of rats is
shown and described in Supplementary Figure 4B.
VPA Preparation and Treatment
Sodium VPA (P4543, Sigma, St. Louis, MO, USA) was diluted
with the cell culture medium to 0.5 mM. VPA in the culture
medium was added to cells 24 h prior to IR treatment. For rats,
sodium VPA was dissolved in sterile saline and injected into
the peritoneum.
Cell Culture and Transfection
The MCF10A cell line was provided by Stem Cell Bank, Chinese
Academy of Sciences, cultured with DMEM/F12 (D9785, Sigma)
and combined with growth factors (37). MCF10A cells were
treated with DMBA at different doses for 24 h then cultured for
around 60 days with fresh medium for transformation. RI-1
(S8077, Selleckchem, Houston, TX, USA) was dissolved with
DMSO, cells treated with 10 mm RI-1 in culture medium for 24 h
post IR treatment. 16HBE and HCC1937 cell lines were
maintained in DMEM with 10% fetal bovine serum (FBS,
Liu et al. VPA Mediates RFWD3-Dependent Rad51 Ubiquitination
Frontiers in Oncology | www.frontiersin.org March 2021 | Volume 11 | Article 6462562
16140071, Gibco, Thermo Fisher, Waltham, MA, USA).
HCC1937 cells were transfected with expression vectors
containing wild-type BRCA1 (pcDNA3-BRCA1, wtBRCA1).
siRFWD3 [siRFWD3-1: GGACCUACUUGCAAACUAUdTdT;
siRFWD3-2: GCAGUCAUGUGCAGGAGUUdTdT (18, 38)]
was transfected with lipofectamine 2000 (12566014, Thermo
Fisher) in accordance with the manufacturer’s instructions.
Inhibition of Apoptosis
Z-VAD-FMK (HY-16658B, MedChemExpress, Monmouth
Junction, NJ, USA) was dissolved in DMSO to 1 mM for
stocking and further diluted by culture medium to 40 mm for a
working solution. Cells were treated by Z-VAD-FMK for 2 h
prior to VPA and IR treatment.
Comet Assay
The neutral and alkaline comet assay were performed on the
Trevigen Comet Assay kit (Cat. 4252-040-K, Trevigen,
Gaithersburg, Maryland, USA). Cells were pretreated with 0.5 mM
VPA for 24 h followed by 8 Gy IR treatment. Low melting agar
was combined with cell suspension at a ratio of 1:10 after
treatments, then spread onto comet slide immediately. The
slides were cooled for 30 min, then immersed in lysis solution.
Slides were immersed into cold alkaline unwinding solution
for 1 h (alkaline comet), then transferred into neutral or
alkaline electrophoresis buffer at 21 V for 30 min at 4°C in the
dark. The slides were washed twice in distilled water and 70%
ethanol for 5 min, then dried and stained with SYBR gold
(1:10000, Trevigen).
Immunofluorescence
This protocol was described in our previous studies (39). Primary
antibodies included: gH2AX (1:500; 05-636, EMD Millipore,
Burlington, MA, USA), Rad51 (1:100; sc8349, Santa Cruz,
Dallas, TX, USA), BRCA1 (1:100; sc-6954, Santa Cruz), and
53BP1(1:1000; NB100-304, Gene Tex, Irvine, CA, USA), RFWD3
(1:200; 19893-1-AP; Proteintech, Wuhan, China). Secondary
antibodies consisted of Alexa Fluor® 594 goat anti-mouse lgG
(H+L) (1:300; A11032, Molecular probes, Waltham, MA, USA)
and Alexa Fluor® 488 chicken anti-rabbit lgG(H+L) (1:300;
A21441, Molecular probes, Thermo Fisher).
Western Blotting
The protocol was described in our previous publication (40).
Primary antibodies included: BRCA1 (1:200; sc-6954, Santa
Cruz), Rad51 (1:200; sc-8349, Santa Cruz), Rad51 (1:2000;
PC130, Calbiochem, Burlington, MA, USA), P53 (1:200; sc-98,
Santa Cruz), P21 (1:150; 556431; BD, New York, NY, USA),
RFWD3 (1:500; 19893-1-AP; Proteintech, Wuhan, China),
Ubiquitin (1:1000; 3936s; Cell Signaling Technology, Trask
Lane Danvers, MA, USA), b-actin (1:2000; TA-09, ZSGB-BIO,
Beijing, China) and GAPDH (1:2000; TA-08, ZSGB-BIO).
Secondary antibodies were goat anti-mouse lgG (H+L) (1:5000;
31430, Thermo Fisher) and goat anti-rabbit lgG (H+L) (1:5000;
31460, Thermo Fisher).
Immunoprecipitation
Whole-cell lysate was mixed with Rad51 antibody (40ul/1mg
protein lysate; PC130, Calbiochem) at 4°C for 3 h, protein-A
dynabeads were added to the lysate-antibody mixture at 4°C
overnight. The mixture was washed four times and then
denatured at 95°C for 5 min. The subsequent steps were the
same as the regular Western blot described above.
Clonogenic Survival and Serum-Starving
Assay
The method of clonogenic survival assay was described elsewhere
(41). For the serum-starving assay, we used cells at the number of
1 × 105 cultured with medium containing or lacking horse serum.
The medium without serum still contained the necessary factors
for maintaining the proliferation of MCF10A cells.
Soft Agar Colony Formation Assay
For the bottom layer, 1.5 ml/well 0.6% low-melting agar (214230,
Difco Agar Nobel, BD) was added to a six-well plate for
solidification. The top layer contained cell suspension (1 × 104/
well) and 0.3% agar. The cells were cultured for 3 to 4 weeks until
a visible colony formed; these were stained with 0.005% crystal
violet (C8470, Solarbio, Beijing, China).
Animal Keeping and the Establishment of
Breast Cancer Model
Detailed information was described in our previous publication
(33). The experiment was performed in accordance with the
requirements of the Shandong University Human and Animal
Ethics Research Committee (81472800, approved March 2014).
In brief, around 40 to 60 days after a single dose of 20 mg DMBA
gavage to female Sprague Dawley (SD) rats, lumps in breast sites
could be found by palpation (33).
The Detection of VPA Concentration in
Serum
Peripheral blood was collected from the jugular vein of the SD
rats at 15 min, 1 h, 3 h, 6 h, 12 h and 24 h after VPA treatment.
The concentration of VPA in serum was detected by Emit kit
(Emit® 2000 VPA detection kit; Siemens).
Tissue Array Analysis
Tissue arrays were purchased from Shanghai Outdo Biotech
Company (Shanghai, China), which collected 140 breast cancer
tissues and 45 breast para-carcinoma tissues obtained from
different breast cancer patients admitted to the public hospitals
in southern China between 2004 and 2014 and approved by the
Human Research Ethics Committee (HREC) of Taizhou
Hospital of Zhejiang Province, informed consent was signed by
all the patients involved in this study. Immunohistochemistry
staining of Rad51 in tissues was performed and the density (H-
score) of Rad51 expression in the tissues was calculated. Since the
expression of Rad51 in para-carcinoma tissues did not follow a
normal distribution, the median (50%) expression of Rad51 in
para-carcinoma was used to define tumor tissue as of lower (n =
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117) and higher (n = 20) expression. Survival data of the patients
120 months post the sample biopsy was obtained.
Statistical Analysis
Results were presented as means ± standard deviation for the
groups. Data were analyzed by independent sample t-test and
further normalized by Bonferroni post hoc test, survival data in
tissue arrays were analyzed by Kaplan-Meier survival analysis on
SPSS Statistics for Windows, Version 23.0 (Armonk, NY: IBM
Corp; licensed to Shandong University). P < 0.05 indicated a
statistically significant difference.
RESULTS
The Establishment of a DMBA-Induced
Highly Malignant Transformation Cell
Model on Normal Cell MCF10A
To confirm the bidirectional effect of VPA on tumor and normal
cells, we sought to transform normal MCF10A cells to
malignancy by DMBA treatment and establish a paired cell
line. First, a suitable dose of DMBA treatment on MCF10A
cells was explored through MTT assay. The doses of DMBA over
80 mg/ml exhibited increasing cytotoxicity (Figure 1A), so doses
less than 80 mg/ml DMBA were chosen to treat the normal
MCF10A cell for 24 h and further cultured for around 60 days.
Compared with the normal cells, 20 mg/ml DMBA-treated cells
exhibited stronger ability to form colonies on the soft agar-
colony formation assay (Figure 1B), demonstrated increased
proliferating ability on the cell clonogenic assay (Figure 1C,
P < 0.01), decreased E-CAD protein levels and increased a-SMA
protein levels (Figure 1D), thus suggesting that DMBA was able
to cause malignant transformation of normal cells (42–44). To
verify this paired cell line, we next performed RNA sequencing
analysis to detect the differential gene expression (Figure 1E).
We found 909 up-regulated genes and 726 down-regulated genes
in the DMBA-treated cells as compared with normal cells
(Figure 1F). KEGG pathway analysis further indicated that the
changed-genes were highly associated with breast cancer and
other cancer (small cell lung cancer, prostate cancer, and renal
cell carcinoma) pathways (Figure 1G, left panel: up-regulated,






FIGURE 1 | The establishment of a DMBA-induced malignant transformation cell model on normal cell MCF10A. (A) MTT assay was performed for the toxicity
detection of DMBA on MCF10A. (B) Soft agar assay showed the forming colonies after 4 weeks of culturing to identify cell transforming. (C) Cells were cultured
under different serum conditions to detect their growth ability to identify cell transforming. (D) The expression of E-CAD and a-SMA was detected by Western blot
both on 0 and 20 mg/ml DMBA-treated MCF10A cells. (E) The heat map from RNA sequencing analysis showed the differentially expressed genes between 20 and 0
mg/ml DMBA-treated cells. (F) Scatter plot (left) and volcano plot (right) exhibited the changed-genes between the two cell lines. (G) Genes were analyzed by KEGG
database for clustering functional pathways, enrichment score was used as the measurements. Each data point in the graph was from three independent
experiments (mean ± SD); P-values were calculated by t-test (**P < 0.01).
Liu et al. VPA Mediates RFWD3-Dependent Rad51 Ubiquitination
Frontiers in Oncology | www.frontiersin.org March 2021 | Volume 11 | Article 6462564
demonstrated that 20 mg/ml DMBA resulted in MCF10A cell
transformation, and a stabilized DMBA-induced malignant
transforming cell model was successfully established.
VPA Sensitizes Transformed cells While
Protecting Normal Cells After IR
Treatment by Regulating the Rad51-
Mediated HR Pathway
To investigate the effect of VPA on both the DMBA-induced
transformed cells and normal cells after IR treatment, we next
treated the cells with 0.5 mM VPA for 24 h prior to IR.
First, DSB levels were measured in the paired cell line. By
neutral comet assay, we found that DSB levels in the VPA-treated
DMBA-transformed cells were increased at 0 min, 30 min, and
120 min post-IR (Figure 2A, left panel; P<0.01). However, in the
untransformed normal cells, decreased DSB levels were observed
in the combination group at 30 min and 120 min post-IR (Figure
2A, right panel; P < 0.01). The results were validated by the
alkaline comet assay (Supplementary Figure 1A). To further
detect the DSB levels in the cells, we next explored the foci
formation of DSBs markers, gH2AX and 53BP1, by
immunofluorescence. High levels of DSBs were detected at 6 h
post-IR in both transformed and normal cells (Figure 2B,
Supplementary Figure 1B). Cells with gH2AX or 53BP1 foci
were divided into two groups at 6 h post-IR treatment: lower (L)
type (under 20 foci per cell) and higher (H)-type (over 20 foci per
cell). In the transformed cell, VPA enhanced the H-type cells at
6 h post-IR treatment (P < 0.01), and there were persistent
gH2AX and 53BP1 foci cells with concomitant VPA treatment at
24 h post-IR (P < 0.01, Figure 2B left panel, Supplementary
Figure 1B left panel). In contrast, in the normal cells, there was
no significant difference in the percentage with L-type and
H-type cells between the groups. Noticeably, VPA attenuated
the gH2AX or 53BP1 foci cells at 24 h post-IR treatment (Figure
2B right panel, Supplementary Figure 1B right panel). These
results demonstrated an elevated DSBs in the transformed cell
line as compared to decreased DSBs levels in the normal cell line
with VPA neoadjuvant treatment before IR.
Next, cell survival was measured in both cell lines by






FIGURE 2 | VPA sensitizes transformed cells while protects normal cells after IR treatment by regulating the Rad51-mediated HR pathway. (A) Transformed cells
(left panel) and normal cells (right panel) were pretreated with VPA for 24 h and then subjected to 8 Gy IR. The DSB levels of cells at the indicated time points post-IR
were detected by neutral comet assay. (B) Immunofluorescence staining of gH2AX foci at 6 and 24 h post-IR. The percentage of L-type and H-type cells containing
gH2AX foci was showed in the graph. (C) The survival of transformed and normal cells was detected by colony formation assay. (D) At 6 h post-IR, transformed and
normal MCF10A cells were subjected to Western blotting. (E) Rad51 foci formation by immunofluorescence. (F) At 6 h post-IR, the percentage of gH2AX and Rad51
colocalized cells were showed in the graph. The colony formation and graph showed the cell survival both in (G) transformed and (H) normal cells under RI-1
inhibition on Rad51. Each data point in the graph was from three independent experiments (mean ± SD); P-values were calculated by t-test (*P < 0.05, **P < 0.01).
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survival of transformed cells but promoted the survival of normal
cells with IR treatment (Figure 2C). Similarly, VPA also
promoted the survival of human bronchial epithelial cell line,
16HBE, in response to IR treatment (Supplementary Figure
1C), thus confirming the effect of VPA on normal cells was
distinct to the DMBA-transformed malignant cells. Collectively,
our results indicated that VPA renders radiosensitization on
DMBA-induced transformed cells and radioprotection on
normal cells.
To examine whether VPA-mediated dual-role effect was
associated with DNA repair function in both cell lines, we
measured the protein level and foci formation of key proteins
in the NHEJ and HR pathways. We found the protein level of
NHEJ key proteins, including Ku70/80 and DNA-PKcs, were not
noticeably affected by VPA treatment in our working system
(Supplementary Figure 1D), indicating that NHEJ pathway was
not significantly affected by VPA treatment in this working
system. However, we observed that VPA inhibited the protein
level of Rad51 and BRCA1 of the HR pathway in the transformed
cells with IR treatment (Figure 2D). Meanwhile, to confirm the
effect of VPA on malignant cells, we also tested the expression of
Rad51 and BRCA1 in several breast cancer cell lines including
MCF7, MDA-MB-231, and EUFA423. VPA inhibited the protein
expression of Rad51 and BRCA1 upon IR treatment in those
breast cancer cell lines (Supplementary Figure 1E, upper panel),
which was consistent with the finding in the transformed cells. In
contrast, in the normal MCF10A cells, the protein expression of
Rad51 and BRCA1 were not noticeably affected by VPA and IR
treatment (Figure 2D) and were found to be increased in the
16HBE cells (Supplementary Figure 1E, lower panel). The
percentage of cells containing Rad51 and BRCA1 foci was
reduced by VPA in the transformed cells and was increased in
the normal cells following VPA and IR treatment (Figure 2E,
Supplementary Figure 1F). We also observed that VPA
decreased the number of cells with Rad51 and gH2AX foci
colocalization after IR treatment in the transformed cells at 6 h
post-IR treatment (P < 0.01), but not in the normal cells (Figure
2F). These results indicated that the Rad51-mediated HR
function was inhibited by VPA in the transformed cell lines,
while it was preserved in the normal cell lines upon IR treatment.
To investigate whether the VPA-mediated bidirectional effect
on transformed and normal cells is Rad51-dependent, the Rad51
inhibitor, RI-1, which covalently binds to the cysteine 319 on the
surface of Rad51 protein for destabilization (45), was employed
for the next series of study. A 10 mMRI-1 can significantly inhibit
Rad51 protein expression in both transformed and normal
MCF10A cells (Supplementary Figure 2A). Rad51 inhibition
leads to a more sensitive phenotype to IR treatment and
compromised the radiosensitization effect of VPA (Figure 2G).
However, in the normal MCF10A cells, Rad51 inhibition also
compromised this protection effect under IR treatment (Figure
2H), which was further validated by the 16HBE cell line
(Supplementary Figure 2B). We also confirmed that BRCA1
played a similar effect as Rad51 using an isogenic paired cell line
of HCC1937 with and without BRCA1 expression, which
demonstrated the radiosensitization effect of VPA was
compromised by BRCA1-deficiency (Supplementary
Figure 2C).
The above results demonstrated that the bidirectional effect of
VPA was associated with Rad51-mediated HR function. VPA
preserved HR through regulating BRCA1-Rad51 for protecting
normal cells under IR treatment, while disrupted HR function
leading to destroying transformed cells.
VPA Affects Rad51 Stability and
Ubiquitination During the Bidirectional
Process
To explore whether the change in Rad51 protein level was
associated with its protein stability, cycloheximide (CHX), a
protein synthesis inhibitor, was added to the paired cells and
Rad51 protein level was subjected to western blot. In the
transformed cell, the Rad51 half-life was shortened in the VPA
alone (4.08 h, P < 0.01) and combination treatment (2.42 h,
P < 0.01) groups as compared with untreated (6.06 h) and IR
(5.90 h) groups (Figure 3A). In contrast, in the MCF10A normal
cells, we found the half-life of Rad51 protein was significantly
prolonged by VPA treatment both in the VPA alone (8.07 h,
P < 0.01) and combination treatment (>8 h, P < 0.01) group as
compared with untreated (4.93 h) and IR (6.82 h) groups (Figure
3B). Similar results were detected with BRCA1 protein in the
transformed cells (untreated, 8.04 h; VPA, 3.30 h; IR, 6.75 h;
VPA+IR, 3.18 h; Supplementary Figure 3A) and normal cells
(untreated, 5.54 h; VPA, 7.11 h; IR, 3.42 h; VPA+IR, 8.06 h;
Supplementary Figure 3B).
Since we discovered that the Rad51 protein stability was related
to the VPA-mediated bidirectional effect, it is necessary to detect its
ubiquitination in the paired cell line. We used the 26S proteasome
inhibitor, MG132 to treat cells for 6 h before harvesting. Figure 3C
showed the effect of VPA on Rad51 protein levels in both the
transformed and normal cells were restored by MG132. We found
that the ubiquitination of Rad51 was increased in transformed cells
and decreased in normal cells by the combined treatment as
compared to IR alone (P<0.01, Figure 3D). Our data suggested
that VPAs exhibited a bidirectional role in transformed and normal
cells by regulating Rad51 ubiquitination.
RFWD3-Dependent Rad51 Ubiquitination
Is Involved in the Observed VPA-Mediated
Bidirectional Effect
It was reported that E3 ligase, RFWD3, can directly interact and
ubiquitinate Rad51, thus the effect of RFWD3 was investigated in
our working system. In the transformed cells, the protein level of
RFWD3 in the VPA+IR combination group was increased as
compared with IR alone; in contrast, the combined treatment of
VPA and IR decreased RFWD3 expression compared with IR alone
in the normalMCF10A cells (Figure 4A). The change of RFWD3 in
the combination group was confirmed in MCF7, MDA-MB-231,
and EUFA423 breast cancer cell lines and normal 16HBE cell line
(Supplementary Figure 3C). The protein expression was increased
in cancer cells and decreased in normal cells, indicating that the
VPA-mediated bidirectional effect was associated with RFWD3.We
next found that both RFWD3 and Rad51 were in a protein complex
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by co-immunoprecipitation experiment in the three cell lines
(Figure 4B), and both protein foci formation co-localized
together after IR treatment (Figure 4C), suggesting that there was
an association between these two proteins. To test whether there is a
functional link between RFWD3 and Rad51 in our working system,
we next established the cell line with interfered RFWD3 by its
siRNA (Figure 4D, Supplementary Figure 3D). After disrupting
RFWD3 in the transformed cells, Rad51 protein level in the
combination group was increased, and its ubiquitination was
decreased significantly as compared with IR alone (Figures 4D, E);
whereas in the normal cells, the change of Rad51 protein level
and its ubiquitination in the combination group was the
opposite (Figures 4D, E). Thus, the data demonstrated
RFWD3-dependent Rad51 ubiquitination was involved in the
VPA-mediated bidirectional effect.
VPA Targets RFWD3 for Bidirectional
Regulation on HR Activity In Vivo
In our previous studies, the DMBA-induced breast tumor on
female SD rats was demonstrated to be a stable primary breast
tumor model (33, 46–48). Using this animal model
(Supplementary Figure 4A), the function of RFWD3 was
confirmed. We subjected the rat tumor model to a total of 8
Gy IR over 4 days (Supplementary Figure 4B, left panel). Some
studies have reported that the recommended therapeutic
equivalent doses of VPA for RT ranged from 150 to 600 mg/kg
(31, 49). We have opted for 200 mg/kg (i.p.) VPA as this was the
same as that used to treat the cells (0.5 mM) in our working
system (Supplementary Figure 4C).
When compared to the untreated group, the rate of tumor
growth in the VPA alone group was slower (P < 0.01, Figure 5A).
After the administration of both VPA and IR, tumor growth was
significantly inhibited comparing to IR alone (P < 0.01, Figure
5A), the DSBs detected by gH2AX was enhanced (Figure 5B),
the protein level of Rad51 was inhibited (Figure 5B), but
RFWD3 protein level was increased (Figure 5B) as compared
with IR treatment alone. The data concur with the above results
obtained from the paired in vitro cell line. Our previous study
uncovered that P53 can suppress the hyper-recombination by
modulating BRCA1 and Rad51 (41), here we found that VPA
increased the protein level of P53 and P21 in tumor tissue cells
under IR treatment (Supplementary Figure 4D).
A B
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FIGURE 3 | VPA affects Rad51 stability and ubiquitination. After VPA and IR treatments, (A) transformed MCF10A cells and (B) normal MCF10A cells treated with
40 mg/ml CHX for 0, 2, 4, and 8 h. The expression of Rad51 was detected by Western blot. Cells treated with 40 mM MG132 at 6 h before whole-cell extracts
harvesting. (C) Rad51 protein expression was detected by Western blot and the (D) ubiquitination on Rad51 was detected by immunoprecipitation. Bands in the
graphs were quantified by ImageJ software (Wayne Rasband). Each data point in the graphs was from three independent experiments (mean ± SD); P-values were
calculated by t-test (**P < 0.01).
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FIGURE 4 | RFWD3-dependent Rad51 ubiquitination is involved in the VPA-mediated bidirectional effect. (A) RFWD3 protein expression was detected with VPA and
IR treatment. (B) The interaction between RFWD3 and Rad51 proteins was detected by protein beads containing Rad51 antibody through Western blot. (C) The foci
formation of RFWD3 and Rad51 in this paired cell was detected at 6 h post-8 Gy IR. Co-localization of RFWD3 and Rad51 proteins was shown in the figure. The
scale bar represented as 10µm. (D) siRNA was designed to abolish the function of RFWD3 and the expression of Rad51 under those treatments was detected by
Western blot. (E) Ubiquitination of Rad51 on transformed and normal MCF10A cells after RFWD3 depletion was detected by Western blot. Bands in the graphs were
quantified by ImageJ software (Wayne Rasband). Each data point in the graph was from three independent experiments (mean ± SD); P-values were calculated by




FIGURE 5 | VPA targets RFWD3 for bidirectional regulation on HR activity in vivo. (A) Left panel: tumor volume of DMBA-induced primary breast cancer rats after
treatment was normalized by the untreated group (n = 10 in each group). Right panel: tumors dissected from rats at the 35th day post-treatment. (B) Protein
expression in tumor tissue was detected by specific antibodies through Western blot. (C) The survival rate of tumor rats following VPA and IR treatment (n = 10 in
each group). (D) Proteins expression in normal tissues under VPA or IR were detected by specific antibodies through Western blot. Bands in the figures were
quantified by ImageJ software (Wayne Rasband); each data point in the graph was from three independent experiments (mean ± SD); P-values were calculated by
t-test (**P < 0.01).
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We observed that the survival rate of the rats with breast
cancer was significantly decreased after IR treatment, this was
ameliorated with VPA administration (P<0.01), thus implying a
protective effect of VPA on the rats (Figure 5C). Therefore, we
next investigated the status of abscopal normal tissues subjected
to the in vivo treatments. After the combination treatment, the
spleen, liver, lung, and brain tissues demonstrated that the levels
of DSBs as detected by gH2AX were attenuated, while Rad51
protein levels were enhanced, and the protein levels of RFWD3
were decreased (Figure 5D), P53 and P21 protein expressions
were also inhibited (Supplementary Figure 4E), as compared
with IR treatment.
Thus, we demonstrated that the bidirectional effect of VPA in
vivo through this animal tumor model during IR treatment was
consistent with the findings from the in vitro cell lines. The VPA-
mediated bidirectional effect was RFWD3-dependent and
triggers Rad51-associated HR function.
Higher Level of Rad51 in Human Breast
Cancer May Be Associated With Poor
Prognosis and Supported to be the Marker
for Tumor Therapy
To investigate the association of Rad51 with the malignant
carcinoma development and the significance of VPA in clinical
application, IHC of Rad51 was performed in tissue arrays
(Figure 6A) containing the samples of para-carcinoma breast
tissues (n = 35) and breast tumor tissues (n = 79, Figure 6B).
Rad51 expression in tumor tissues was higher than the
expression in para-carcinoma tissues (P < 0.05, Figure 6C).
Combining with the survival rate data for these patients, the
results indicated that higher expression of Rad51 was associated
with poor prognosis (P < 0.05, Figure 6D). This finding was
triangulated with the concomitant dataset (P < 0.01; fold change,
4.969; n = 82, Figure 6E) and Kaplan-Meier plotter data set (P <
0.01; n = 3951; Figure 6F). The data suggested that Rad51 was
involved in the oncogenic process and may serve as a significant
marker and target of breast cancer in tumor therapy.
DISCUSSION
Here, we have established a transformed cell model using normal
MCF10A cells and the environmental carcinogen, DMBA, and
verified its characteristics of malignancy. Using both the
transformed and normal MCF10A cell lines, we confirmed the
radiosensitization effect of VPA on malignant cells and
discovered the radioprotective effect of VPA on normal breast
cells and found a molecular mechanism for this bidirectional
effect of VPA, which target E3 ligase RFWD3-dependent Rad51
ubiquitination. The findings were further validated by the well-
A B C
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FIGURE 6 | A higher level of Rad51 in human breast cancer may be associated with poor prognosis. (A) Human breast tumor tissue array was stained through
immunohistochemistry by specific antibody, slides were digitally scanned and subjected to QuantCenter analysis. H-score was used to value the level of Rad51
expression. (B) Rad51 expression level in para-carcinoma tissues defined the standard of lower and higher level of Rad51 expression in breast tumor tissues.
(C) The expression of Rad51 in para-carcinoma (P-Rad51, n = 35) and breast tumor (T-Rad51, n = 101) was counted in the graph. (D) The survival rate of patients
who contributed the breast tumor tissue was calculated using the follow-up data of 120 months. (E) Rad51 expression level on a concomitant dataset was used to
confirm the findings on tissue array. (F) Kaplan-Meier plotter (http://kmplot.com) was used to evaluate the association between prognosis and Rad51 expression.
The number of patients who survived at different follow-up times was listed below the graph. Each data point in the graph was from three independent experiments
(mean ± SD); P-values were calculated by t-test (*P < 0.05, **P < 0.01).
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established DMBA-induced breast cancer animal model. We also
found that the high level of Rad51 was associated with invasive
tumorigenesis and poorer prognosis in breast cancer patients.
Thus, our findings uncovered the novel mechanism of
bidirectional effect of VPA under IR treatment both in vitro
and in vivo, VPA can directly target RFWD3 and then trigger
Rad51 ubiquitination during cancer radiotherapy and limit
radiotoxicity on normal cells (Figure 7).
The Model of DMBA-Induced
Transforming Cell and Animal Is
Reliable for Tumor Study
Cell and animal-derived cancer models are usually established by
the treatment of carcinogenic chemicals (50–52). DMBA as a
prototypical polycyclic aromatic hydrocarbon (PAH) has been
demonstrated to be carcinogenic with high cytotoxicity and
immunotoxicity (42). Studies employed DMBA to establish
multiple cancer models in animals, these include breast, oral, skin,
and lung cancers (48, 53–55). DMBA is also used to induce the
transformation of normal human breast epithelial cell MCF10A (42,
56). In this study, we established a stable transformed MCF10A cell
line, and RNA-seq analysis found that breast cancer and other
cancer pathways were activated, thus confirming the malignancy in
this transformed cell line. In our previous studies, we have
established the primary breast cancer model on female SD rats by
DMBA (33). Both the DMBA-transformed cell and animal models
effectively mimicked the tumorigenesis and the features of
malignancy of human breast cancer. The successful establishment
of these two models plays a great significance for the comparative
study of tumor cells and normal cells in cancer prevention and
treatment, as well as the study on the mechanism of tumorigenesis.
Therefore, in the current study, the use of both models aims to
triangulate the molecular mechanism of VPA-mediated
bidirectional role in cancer radiotherapy.
FIGURE 7 | Working model illustrates the radiosensitizing and radioprotection effect of VPA. VPA sensitizes malignantly transformed cells while protects normal cells
to IR treatment. VPA enhances the DSBs level in malignant cells and alleviates the DSBs level in normal cells through regulating HR function. RFWD3 is targeted by
VPA to manipulate the ubiquitination of Rad51. VPA inhibites RFWD3 to decrease the ubiquitination of Rad51 in normal cells in response to IR-induced DSBs,
protecting Rad51 from degradation, while the ubiquitination is enhanced in malignant cells.
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Up-Regulation of RFWD3-Dependent
Rad51 Ubiquitination Plays a More Direct
Role in VPA-Mediated Radiosensitization
in Tumor Cells
As we have previously known, Rad51 plays a pivotal role in the
HR process to repair damaged DNA. Studies from our and other
groups suggested that VPA can suppress Rad51 activity for the
radiosensitization to breast cancer cells (33, 57). Since Rad51 is
an effector in the DNA damage signaling pathway, it would be
necessary to explain how Rad51 protein level was down-
regulated in the cellular process. In this study, we found that
the decrease of Rad51 is associated with the increase of its
ubiquitination in VPA-mediated radiosensitization for tumor
cells in both the in vivo and in vitro working systems. The
increase of Rad51 ubiquitination was caused by an E3 ligase,
RFWD3. Therefore, VPA probably directly upregulates RFWD3
and then initiates Rad51 ubiquitination to disrupt the HR
function so as to enhance IR effect for killing cancer cells.
Some studies reported that the ubiquitination of DNA damage
and repair-related proteins are important for keeping HR
function (13, 19), RFWD3 as an E3 ligase can interact and
ubiquitinate Rad51 to promote Rad51 timely removal from the
damaged sites to regulate HR activity (18).
The NHEJ is another major pathway for DSBs repair in
mammalian cells, which use little or no homologous template
(58). DNA-PKcs and Ku proteins play a major role during NHEJ
(59), however, the expression of these key proteins in NHEJ was
not significantly altered following VPA and IR treatment in our
current study, both in the transformed and normal cell lines,
which is inconsistent with the results on MCF7 and U2OS cells
(33, 57). Due to the characteristic difference and the phenotype
between cell lines, the VPA-regulated effect may be different
between cell lines, which requires further investigation.
Down-regulation of RFWD3-Dependent
Rad51 Ubiquitination Was Required
for VPA-Mediated Radioprotection
in Normal Cells
Since it was found VPA can radiosensitize tumor cells, it would be
essential to understand how VPA influences normal cells during
tumor RT. In the current study, VPA exhibited a radioprotective
effect on normal cells both in vivo and in vitro, consistent with other
studies, which reported VPA to be radioprotective in normal
neuron cells (31, 32, 34), that total body IR-induced lethality of
mice wasmitigated by concomitant VPA (35), and VPA rescued the
hair loss and enhanced the survival in high-grade glioma patients
during RT (36). However, the mechanism of VPA-mediated
radioprotection in normal cells is still unknown. In the present
study, we found that the mechanism of VPA in normal cells was
opposite to tumor cells, RFWD3-dependent Rad51 ubiquitination
was down-regulated, which means that VPA-mediated
radioprotection was associated with preserving Rad51 activity and
avoiding its ubiquitination by RFWD3. Therefore, RFWD3 serves a
different function in normal cells and tumor cells, and VPA can
initiate the key switch of RFWD3-related ubiquitination to have a
radio-bidirectional effect.
The VPA-Mediated RFWD3-Dependent
Bidirectional Effect Was Most Notable
Upon IR Treatment
However, in the VPA alone treatment, we found that RFWD3
was upregulated compared to the untreated group in the
transformed cells, and the Rad51 expression was slightly
downregulated while the ubiquitination of Rad51 was
upregulated marginally. Correspondingly, in the normal cells,
RFWD3 was inhibited following the treatment of VPA alone, the
ubiquitination of Rad51 was marginally affected, while the
expression of Rad51 did not enhance but was preserved at a
similar level as the untreated group. Thus, we speculate that this
VPA-mediated RFWD3-dependent regulation effect was most
notably by IR-induced high-level of ubiquitination.
Lateral Pathways May Potentially Involve
in the VPA-Mediated Radio-Bidirectional
Effect
Some studies demonstrated that VPA can enhance the efficiency of
chemotherapy and radiotherapy by affecting apoptosis and cell cycle
pathways (60, 61). We explored the dominant role of Rad51
ubiquitination in apoptosis by detecting the biological phenotypes
under inhibiting the observed apoptosis and the RFWD3-mediated
Rad51 ubiquitination function (Supplementary Figure 5A).
Employing the pan-caspase inhibitor, Z-VAD-FMK, which can
inhibit and reverse the apoptotic event (62), we found that the
effect of VPA on Rad51 ubiquitination was not affected both in the
transformed and normal MCF10A cells (Supplementary Figures
5A, B). Importantly, si-RFWD3 transfection caused inhibition of
Rad51 ubiquitination compromised the VPA-mediated
bidirectional effect upon IR treatment in these two cells
(Supplementary Figure 5C). The data suggested that Rad51
ubiquitination was prior to apoptosis.
Our previous studies indicated that VPA can sensitize breast
cancer cells to chemotherapy and IR treatments by inhibiting the
HR function, such VPA-mediated HR inhibition was not
associated with the cell cycle (47, 63). Since we have employed
the same treatments (0.5 mM VPA and 8 Gy IR) in the present
working system, therefore the cell cycle would not be involved
into the VPA-mediated bidirectional effect.
Due to the complicated intracellular functions during DDR,
there may be multiple modification pathways involving in this
VPA-mediated radio-bidirectional effect, which required
further investigation.
VPA Shows Perspective Application on
Clinical RT
At present, the effectiveness of RT is limited by the toxicity to
normal cells during IR treatment, hence locating a safe and
efficacious adjuvant treatment to alleviate IR-induced damage in
normal cells while sensitizing tumor cells to IR has attracted
much clinical attention. VPA is a potential candidate with its
dual radioprotective and radiosensitizing effects (64, 65). We
believe that the findings of this radio-bidirectional effect of VPA
and its molecular mechanism will spur further investigation into
VPA’s clinical application in cancer therapy.
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Supplementary Figure 1 | (A) Normal cells (left panel) and transformed cells
(right panel) were pretreated with VPA for 24h and subjected to 8Gy IR. The
DNA DSBs level of cells at 0min, 30min, and 120min post-IR were detected by
(A) alkaline comet assay. By immunofluorescence, (B) 53BP1 foci formation in
the paired cells was presented. The percentage of L-type and H-type of the cells
containing 53BP1 foci was showed the graph. The survival of (C) 16HBE cell was
detected by colony formation assay. The cell survival fraction in the difference
between groups was shown in the graph. At the time of 6h post-IR, (D) normal,
transformed MCF10A and (E) breast tumor cell lines MCF7, MDA-MB-231,
EUFA423 and normal 16HBE cells were subjected to western blotting. (F) At the
time of the 6th and 24th hour, treated cells were delivered to immunofluorescence
assay. BRCA1 foci formation was showed in the pictures, columns in the graphs
presented the cell percentage expressed protein foci. Each data point in the graph
was from three independent experiments (mean ± SD); P-values were calculated by
t-test (*P<0.05, ** P<0.01).
Supplementary Figure 2 | (A) 10mM RI-1 inhibited the expression of Rad51
protein after 24h- pretreatment with VPA before 8Gy IR treatment. (B) RI-1 working
system was performed on 16HBE ells. Colony formation assay on 16HBE cells
showed the survival fraction and the quantification graph was showed in figure.
(C) The stable expressed cell line of BRCA1-deficient and BRCA1-proficient was
successfully established by the BRCA1-deficient cell line, HCC1937. By western
blot, the BRCA1 protein level was detected in the isogenic paired cells. MCF7 was
used as a positive control of BRCA1 expression. By colony formation assay, cell
survival in the paired cell lines was performed after different treatments. Each data
point in the graphs was from three independent experiments (mean ± SD); P-values
were calculated by t-test (** P<0.01).
Supplementary Figure 3 | After VPA and IR treatments, (A) transformed and
(B) normal MCF10A cells were treated with 40mg/ml CHX for 0h, 2h, 4h, 8h. The
expression of BRCA1 was detected by western blot. (C) RFWD3 protein expression
was detected in MCF7, MDA-MB-231, EUFA423, 16HBE cells following VPA and
IR treatments. (D) siRNA was designed to abolish the function of RFWD3 and the
expression of Rad51 under those treatments was detected by western blot. Notes:
bands in the graphs were quantified by ImageJ software (Wayne Rasband). Each
data point in the graphs was from three independent experiments (mean ± SD);
P-values were calculated by t-test (** P<0.01).
Supplementary Figure 4 | (A) Primary breast tumor model was induced by
environmental carcinogen DMBA. The schematic diagram of the distribution of
normal breast (left upper panel) and DMBA-induced primary breast tumor (left lower
panel) is shown in figure. The pathological morphology of this primary tumor model
is exhibited (right panel). (B) The schedule of VPA administration and 2Gy ×4 days of
IR treatment. VPA was injected into rats every 12h. VPA injection was performed
before and after the daily 2Gy irradiation, total 12 times of VPA injection (left panel).
Breast tumors on rats were pulled to a side of the body to avoid direct irradiation on
normal tissues, the irradiation field was adjusted to the size of the tumors to ensure
accurate targeting on tumor (right panel). (C) The dynamic concentration of VPA in
serum was detected by a pharmacokinetic assay on SD rats. VPA solution at
different concentrations were delivered to rats by gavage (i.g.) or intraperitoneal
injection (i.p.). Whole blood from the jugular vein at time points was centrifuged for
the VPA detection in serum. (D-E) proteins expression were detected by specific
antibodies through western blot. Notes: each data point in the graph was from three
independent experiments (mean SD).
Supplementary Figure 5 | (A) The protein expression of total caspase3, cleaved
caspase3 and RFWD3 were detected under VPA and IR treatment or the inhibition
of caspase-mediated apoptosis by Z-VAD-FMK and the transfection of si-RFWD3
both in transformed and normal MCF10A. (B) The comparison of the VPA+IR and
the IR alone group under si-RFWD3 or not in transformed and normal MCF10A
through quantified intensity of protein bands. (C) The ubiquitination of Rad51 in
those two cells were detected under VPA and IR treatment or the inhibition of
caspase-mediated apoptosis by Z-VAD-FMK and the transfection of si-RFWD3.
Notes: bands in the figures were quantified by ImageJ software (Wayne Rasband);
each data point in the graph was from three independent experiments (mean ± SD);
P-values were calculated by t-test (** P<0.01, NS: no significant differences).
REFERENCES
1. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with
targeted drugs. Nat Rev Cancer (2011) 11(4):239–53. doi: 10.1038/nrc3007
2. Schneider U, Besserer J, Hartmann M. Hypofractionated radiotherapy has the
potential for second cancer reduction. Strahlenther Onkol (2013) 189
(12):1078–. doi: 10.1186/1742-4682-7-4
3. FarhoodB,GoradelNH,MortezaeeK,KhanlarkhaniN, Salehi E,NashtaeiMS, et al.
Melatoninas anadjuvant in radiotherapy for radioprotectionandradiosensitization.
Clin Trans Oncol (2019) 21(3):268–79. doi: 10.1007/s12094-018-1934-0
4. Siva S, Lobachevsky P, MacManus MP, Kron T, Möller A, Lobb RJ, et al.
Radiotherapy for Non-Small Cell Lung Cancer Induces DNA Damage
Response in Both Irradiated and Out-of-field Normal Tissues. Clin Cancer
Res (2016) 22(19):4817–26. doi: 10.1158/1078-0432.CCR-16-0138
Liu et al. VPA Mediates RFWD3-Dependent Rad51 Ubiquitination
Frontiers in Oncology | www.frontiersin.org March 2021 | Volume 11 | Article 64625612
5. Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and
repair. Antioxid Redox Signal (2014) 21(2):251–9. doi: 10.1089/ars.2013.5668
6. Mao Z, Bozzella M, Seluanov A, Gorbunova V. Comparison of
nonhomologous end joining and homologous recombination in human
cells. DNA Repair (2008) 7(10):1765–71. doi: 10.1016/j.dnarep.2008.06.018
7. Mason JM, Chan YL, Weichselbaum RW, Bishop DK. Non-enzymatic roles of
human RAD51 at stalled replication forks. Nat Commun (2019) 10(1):4410.
doi: 10.1038/s41467-019-12297-0
8. Thangavel S, Berti M, Levikova M, Pinto C, Gomathinayagam S,
Vujanovic M, et al. DNA2 drives processing and restart of reversed
replication forks in human cells. J Cell Biol (2015) 208(5):545–62. doi:
10.1083/jcb.201406100
9. Mijic S, Zellweger R, Chappidi N, Berti M, Jacobs K, Mutreja K, et al.
Replication fork reversal triggers fork degradation in BRCA2-defective cells.
Nat Commun (2017) 8(1):859. doi: 10.1038/s41467-017-01164-5
10. Zellweger R, Dalcher D, Mutreja K, Berti M, Schmid JA, Herrador R, et al.
Rad51-mediated replication fork reversal is a global response to genotoxic
treatments in human cells. J Cell Biol (2015) 208(5):563–79. doi: 10.1083/
jcb.201406099
11. Petermann E, Orta ML, Issaeva N, Schultz N, Helleday T. Hydroxyurea-stalled
replication forks become progressively inactivated and require two different
RAD51-mediated pathways for restart and repair. Mol Cell (2010) 37(4):492–
502. doi: 10.1016/j.molcel.2010.01.021
12. Chen H, Yang H, Zhu X, Yadav T, Ouyang J, Truesdell SS, et al. m(5)C
modification of mRNA serves a DNA damage code to promote homologous
recombination. Nat Commun (2020) 11(1):2834. doi: 10.1038/s41467-020-
16722-7
13. Bekker-Jensen S, Mailand N. The ubiquitin- and SUMO-dependent signaling
response to DNA double-strand breaks. FEBS Lett (2011) 585(18):2914–9. doi:
10.1016/j.febslet.2011.05.056
14. van Wijk SJ, Fulda S, Dikic I, Heilemann M. Visualizing ubiquitination in
mammalian cells. EMBO Rep (2019) 20(2):1. doi: 10.15252/embr.201846520
15. Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and
treatment. Nat Med (2014) 20(11):1242–53. doi: 10.1038/nm.3739
16. Schwartz AL, Ciechanover A. Targeting proteins for destruction by the
ubiquitin system: implications for human pathobiology. Annu Rev
Pharmacol Toxicol (2009) 49:73–96. doi: 10.1146/annurev.pharmtox.
051208.165340
17. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature
(2009) 458(7237):438–44. doi: 10.1038/nature07960
18. Inano S, Sato K, Katsuki Y, Kobayashi W, Tanaka H, Nakajima K, et al.
RFWD3-Mediated Ubiquitination Promotes Timely Removal of Both RPA
and RAD51 from DNA Damage Sites to Facilitate Homologous
Recombination. Mol Cell (2017) 66(5):622–+. doi: 10.1016/j.molcel.
2017.04.022
19. Elia AE, Wang DC, Willis NA, Boardman AP, Hajdu I, Adeyemi RO, et al.
RFWD3-Dependent Ubiquitination of RPA Regulates Repair at Stalled
Replication Forks. Mol Cell (2015) 60(2):280–93. doi: 10.1016/
j.molcel.2015.09.011
20. Chu WK, Payne MJ, Beli P, Hanada K, Choudhary C, Hickson ID. FBH1
influences DNA replication fork stability and homologous recombination
through ubiquitylation of RAD51. Nat Commun (2015) 6:5931. doi: 10.1038/
ncomms6931
21. Wagner SA, Beli P, Weinert BT, Nielsen ML, Cox J, Mann M, et al. A
proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals
widespread regulatory roles.Mol Cell Proteomics (2011) 10(10):M111.013284.
doi: 10.1074/mcp.M111.013284
22. Qiu Z, Fa P, Liu T, Prasad CB, Ma S, Hong Z, et al. A Genome-Wide Pooled
shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response
to ATR and CHK1 Inhibitors. Cancer Res (2020) 80(16):3305–18. doi:
10.1158/0008-5472.CAN-20-0057
23. Ahmed KM, Pandita RK, Singh DK, Hunt CR, Pandita TK. beta1-Integrin
Impacts Rad51 Stability and DNA Double-Strand Break Repair by
Homologous Recombination. Mol Cell Biol (2018) 38(9):3. doi: 10.1128/
MCB.00672-17
24. Chen X,Wong P, Radany E, Wong JY. HDAC inhibitor, valproic acid, induces
p53-dependent radiosensitization of colon cancer cells. Cancer Biother
Radiopharmaceut (2009) 24(6):689–99. doi: 10.1089/cbr.2009.0629
25. Harikrishnan KN, Karagiannis TC, Chow MZ, El-Osta A. Effect of valproic
acid on radiation-induced DNA damage in euchromatic and heterochromatic
compartments. Cell Cycle (2008) 7(4):468–76. doi: 10.4161/cc.7.4.5405
26. Shoji M, Ninomiya I, Makino I, Kinoshita J, Nakamura K, Oyama K, et al.
Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in
esophageal squamous cell carcinoma. Int J Oncol (2012) 40(6):2140–6. doi:
10.3892/ijo.2012.1416
27. Karagiannis TC, El-Osta A. Modulation of cellular radiation responses by
histone deacetylase inhibitors. Oncogene (2006) 25(28):3885–93. doi: 10.1038/
sj.onc.1209417
28. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, et al.
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic
acid. Int J Cancer (2005) 114(3):380–6. doi: 10.1002/ijc.20774
29. Entin-Meer M, Rephaeli A, Yang X, Nudelman A, VandenBerg SR, Haas-
Kogan DA. Butyric acid prodrugs are histone deacetylase inhibitors that show
antineoplastic activity and radiosensitizing capacity in the treatment of
malignant gliomas. Mol Cancer Ther (2005) 4(12):1952–61. doi: 10.1158/
1535-7163.MCT-05-0087
30. Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human
glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat
Oncol Biol Phys (2004) 59(4):1174–80. doi: 10.1016/j.ijrobp.2004.03.001
31. Thotala D, Karvas RM, Engelbach JA, Garbow JR, Hallahan AN, DeWees TA,
et al. Valproic acid enhances the efficacy of radiation therapy by protecting
normal hippocampal neurons and sensitizing malignant glioblastoma cells.
Oncotarget (2015) 6(33):35004–22. doi: 10.18632/oncotarget.5253
32. Zhang H, Zhang W, Zhou Y, Jiang Y, Li S. Dual Functional Mesoporous
Silicon Nanoparticles Enhance the Radiosensitivity of VPA in Glioblastoma.
Trans Oncol (2017) 10(2):229–40. doi: 10.1016/j.tranon.2016.12.011
33. Liu G, Wang H, Zhang F, Tian Y, Tian Z, Cai Z, et al. The Effect of VPA on
Increasing Radiosensitivity in Osteosarcoma Cells and Primary-Culture Cells
from Chemical Carcinogen-Induced Breast Cancer in Rats. Int J Mol Sci
(2017) 18(5):2–9. doi: 10.3390/ijms18051027
34. Liao GX, Li R, Chen XH, ZhangWQ, Du SS, Yuan YW. SODIUMVALPROATE
PREVENTS RADIATION-INDUCED INJURY INHIPPOCAMPALNEURONS
VIA ACTIVATION OF THE Nrf2/HO-1 PATHWAY. Neuroscience (2016)
331:40–51. doi: 10.1016/j.neuroscience.2016.06.019
35. Brown SL, Kolozsvary A, Liu J, Ryu S, Kim JH. Histone deacetylase inhibitors
protect against and mitigate the lethality of total-body irradiation in mice.
Radiat Res (2008) 169(4):474–8. doi: 10.1667/RR1245.1
36. Watanabe S, Kuwabara Y, Suehiro S, Yamashita D, Tanaka M, Tanaka A, et al.
Valproic acid reduces hair loss and improves survival in patients receiving
temozolomide-based radiation therapy for high-grade glioma. Eur J Clin
Pharmacol (2017) 73(3):357–63. doi: 10.1007/s00228-016-2167-1
37. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-
10A mammary epithelial acini grown in three-dimensional basement membrane
cultures. Methods (2003) 30(3):256–68. doi: 10.1016/S1046-2023(03)00032-X
38. Gong Z, Chen J. E3 ligase RFWD3 participates in replication checkpoint
control. J Biol Chem (2011) 286(25):22308–13. doi: 10.1074/jbc.M111.222869
39. Zhang J, Ma Z, Treszezamsky A, Powell SN. MDC1 interacts with Rad51 and
facilitates homologous recombination. Nat Struct Mol Biol (2005) 12(10):902–
9. doi: 10.1038/nsmb991
40. Feng ZH, Scott SP, Bussen W, Sharma GG, Guo GS, Pandita TK, et al. Rad52
inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci
U S A (2011) 108(2):686–91. doi: 10.1073/pnas.1010959107
41. Dong C, Zhang F, Luo Y, Wang H, Zhao X, Guo G, et al. p53 suppresses
hyper-recombination by modulating BRCA1 function. DNA Repair (2015)
33:60–9. doi: 10.1016/j.dnarep.2015.06.005
42. Kwon YJ, Ye DJ, Baek HS, Chun YJ. 7,12-Dimethylbenz[a]anthracene
increases cell proliferation and invasion through induction of Wnt/b-
catenin signaling and EMT process. Environ Toxicol (2018) 33(7):729–42.
doi: 10.1002/tox.22560
43. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MC.
Regulation of the expression of E-cadherin on human cancer cells by gamma-
linolenic acid (GLA). Cancer Res (1995) 55(21):5043–8.
44. Enescu A, Enescu AS, Florou C, Petrescu F. E-cadherin and alpha-SMA
expression in the epithelial-mesenchymal transition of salivary glands
pleomorphic adenomas. Romanian J Morphol Embryol Rev Roumaine
Morphol Embryol (2014) 55(4):1383–7.
Liu et al. VPA Mediates RFWD3-Dependent Rad51 Ubiquitination
Frontiers in Oncology | www.frontiersin.org March 2021 | Volume 11 | Article 64625613
45. Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller
LL, et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous
recombination in human cells. Nucleic Acids Res (2012) 40(15):7347–57. doi:
10.1093/nar/gks353
46. Wang F, Ma Z, Wang F, Fu Q, Fang Y, Zhang Q, et al. Establishment of novel rat
models for premalignant breast disease. Chin Med J (2014) 127(11):2147–52.
47. Tian Y, Liu G, Wang H, Tian Z, Cai Z, Zhang F, et al. Valproic acid
sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2
hyperphosphorylation-mediated DNA repair pathway. DNA Repair (2017)
58:1–12. doi: 10.1016/j.dnarep.2017.08.002
48. Costa I, Solanas M, Escrich E. Histopathologic characterization of mammary
neoplastic lesions induced with 7,12 dimethylbenz(alpha)anthracene in the
rat: a comparative analysis with human breast tumors. Arch Pathol Lab Med
(2002) 126(8):915–27. doi: 10.5858/2002-126-0915-HCOMNL
49. Zhou Y, Niu J, Li S, Hou H, Xu Y, Zhang W, et al. Radioprotective effects of
valproic acid, a histone deacetylase inhibitor, in the rat brain. Biomed Rep
(2015) 3(1):63–9. doi: 10.3892/br.2014.367
50. Vähätupa M, Pemmari T, Junttila I, Pesu M, Järvinen TAH. Chemical-
Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and
12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA). J Vis Exp (2019)
154):2–3. doi: 10.3791/60445
51. Mohapatra P, Preet R, Das D, Satapathy SR, Siddharth S, Choudhuri T, et al.
The contribution of heavy metals in cigarette smoke condensate to malignant
transformation of breast epithelial cells and in vivo initiation of neoplasia
through induction of a PI3K-AKT-NFkB cascade. Toxicol Appl Pharmacol
(2014) 274(1):168–79. doi: 10.1016/j.taap.2013.09.028
52. Connor F, Rayner TF, Aitken SJ, Feig C, Lukk M, Santoyo-Lopez J, et al.
Mutational landscape of a chemically-induced mouse model of liver cancer.
J Hepatol (2018) 69(4):840–50. doi: 10.1016/j.jhep.2018.06.009
53. Ding M, Lu Y, Bowman L, Huang C, Leonard S, Wang L, et al. Inhibition of
AP-1 and neoplastic transformation by fresh apple peel extract. J Biol Chem
(2004) 279(11):10670–6. doi: 10.1074/jbc.M311465200
54. Feng M, Feng C, Yu Z, Fu Q, Ma Z, Wang F, et al. Histopathological
alterations during breast carcinogenesis in a rat model induced by 7,12-
Dimethylbenz (a) anthracene and estrogen-progestogen combinations. Int J
Clin Exp Med (2015) 8(1):346–57.
55. Dong Y, Zhao Q, Ma X, Ma G, Liu C, Chen Z, et al. Establishment of a new
OSCC cell line derived from OLK and identification of malignant
transformation-related proteins by differential proteomics approach. Sci Rep
(2015) 5:12668. doi: 10.1038/srep12668
56. Kwon YJ, Baek HS, Ye DJ, Shin S, Kim D, Chun YJ. CYP1B1 Enhances Cell
Proliferation and Metastasis through Induction of EMT and Activation of
Wnt/b-Catenin Signaling via Sp1 Upregulation. PLoS One (2016) 11(3):
e0151598. doi: 10.1371/journal.pone.0151598
57. Luo Y, Wang H, Zhao XP, Dong C, Zhang FM, Guo G, et al. Valproic acid
causes radiosensitivity of breast cancer cells via disrupting the DNA repair
pathway. Toxicol Res-Uk (2016) 5(3):859–70. doi: 10.1039/C5TX00476D
58. Weterings E, Chen DJ. The endless tale of non-homologous end-joining. Cell
Res (2008) 18(1):114–24. doi: 10.1038/cr.2008.3
59. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of
human non-homologous DNA end-joining. Nat Rev Mol Cell Biol (2003) 4
(9):712–20. doi: 10.1038/nrm1202
60. Chen CH, Chang YJ, Ku MS, Chung KT, Yang JT. Enhancement of
temozolomide-induced apoptosis by valproic acid in human glioma cell
lines through redox regulation. J Mol Med (Berl) (2011) 89(3):303–15. doi:
10.1007/s00109-010-0707-1
61. Banimohamad-Shotorbani B, Kahroba H, Sadeghzadeh H, Wilson DM,3,
Maadi H, Samadi N, et al. DNA damage repair response in mesenchymal
stromal cells: From cellular senescence and aging to apoptosis and
differentiation ability. Ageing Res Rev (2020) 62:101125. doi: 10.1016/
j.arr.2020.101125
62. Liu HR, Peng XD, He HB, Wang YH, Li Y, He GX, et al. Antiproliferative
activity of the total saponin of Solanum lyratum Thunb in Hela cells by inducing
apoptosis. Pharmazie (2008) 63(11):836–42. doi: 10.1691/ph.2008.8607
63. Luo Y, Wang H, Zhao X, Dong C, Zhang F, Guo G, et al. Valproic acid causes
radiosensitivity of breast cancer cells via disrupting the DNA repair pathway.
Toxicol Res (Camb) (2016) 5(3):859–70. doi: 10.1039/C5TX00476D
64. Berendsen S, Broekman M, Seute T, Snijders T, van Es C, de Vos F, et al.
Valproic acid for the treatment of malignant gliomas: review of the preclinical
rationale and published clinical results. Expert Opin Investig Drugs (2012) 21
(9):1391–415. doi: 10.1517/13543784.2012.694425
65. Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, et al.
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide,
and the Histone Deacetylase Inhibitor Valproic Acid for Patients With
Glioblastoma. Int J Radiat Oncol Biol Phys (2015) 92(5):986–92. doi:
10.1016/j.ijrobp.2015.04.038
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Liu, Lim, Cai, Ding, Tian, Dong, Zhang, Guo, Wang, Zhou and
Feng. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) and the copyright owner(s) are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Liu et al. VPA Mediates RFWD3-Dependent Rad51 Ubiquitination
Frontiers in Oncology | www.frontiersin.org March 2021 | Volume 11 | Article 64625614
